Re : pharmacological prevention of side effects of androgen deprivation therapy, a new challenge?
(2011) European Urology — Vol. 59, n° 1, p. 172-173 (2011)
Files
Tombal-Comments2011-WordsofWisdom.pdf
Restricted Access - Adobe PDF
- 49.95 KB
Details
- Authors
- Abstract
- Smith et al report the results of a double-blind, placebo-controlled phase 3 study designed to prospectively evaluate the benefit of the selective estrogen receptor modulator (SERM) toremifene in preventing long-term side effects of androgen deprivation therapy (ADT). The authors have assigned 1284 ADT-treated prostate cancer patients to toremifene (80 mg orally daily) or placebo for 2 yr. The study has reached the primary end point of reducing the rate of new vertebral fractures; the 2-yr incidence of new vertebral fracture was 4.9% in the placebo group versus 2.5% in the toremifene group, a significant relative risk reduction of 50% (p = 0.05). The incidence of any fracture was 10.1% with placebo and 6.3% with toremifene, a significant relative risk reduction of 38% (p = 0.036). Toremifene also reduced the rate of dyslipidemia: At 2 yr, high-density lipoprotein cholesterol increased by 7.2% and total cholesterol, low-density lipoprotein cholesterol, and triglycerides decreased by 4.7%, 7.0%, and 17.6%, respectively, in patients receiving toremifene (p < 0.001 for each comparison). Venous thromboembolic events (VTEs) were reported in 17 subjects (2.6%; 12 deep venous thromboses, 8 pulmonary embolisms) in the toremifene group and in 7 subjects (1.1%; 6 deep venous thromboses, 3 pulmonary embolisms) in the placebo group.
- Affiliations
Citations
Tombal, B. (2011). Re : pharmacological prevention of side effects of androgen deprivation therapy, a new challenge? European Urology, 59(1), 172-173. https://doi.org/10.1016/j.eururo.2010.10.015 (Original work published 2011)